King Oyster Mushroom

Metadata

Regulatory Status

United States

• Dietary supplement: Available as a dietary supplement (dried powder, extracts) under DSHEA.
• Food status: Widely sold as a culinary mushroom. No specific GRAS determination for concentrated extracts, but the whole mushroom has a long history of safe food use.
• FDA: No specific drug or health claim approvals.

European Union

• Fruiting body: The fruiting body (carpophore) of Pleurotus eryngii has a history of significant consumption within the EU prior to May 15, 1997, and is not classified as a novel food when sold as a food product.
• Mycelium powder: Pleurotus eryngii dehydrated mycelium powder for use in food supplements is classified as a novel food and requires novel food authorization. The European Commission has formally communicated that mycelium-based products lack evidence of compositional equivalence with the fruiting body.
• Health claims: No authorized health claims under EFSA Regulation 1924/2006.

China

• Status: Widely cultivated and consumed as a food mushroom. Not listed in the Chinese Pharmacopoeia as a medicinal substance.
• Commercial cultivation: China is the world’s largest producer of P. eryngii, with industrial-scale cultivation facilities.

Japan and Korea

• Japan: Widely cultivated and consumed under the name “Eringi.” One of the most popular mushrooms in Japanese cuisine. Available as a food; no specific pharmaceutical approval.
• Korea: Major cultivation industry. Consumed as a food mushroom (Saesongi Beoseot). Recognized for functional food potential but no specific health claim approvals.

Conditions & Indications

Primary: Cardiovascular and Lipid Health (Moderate Evidence)

• Cholesterol reduction: Pleurotus eryngii contains naturally occurring lovastatin, an HMG-CoA reductase inhibitor that is the active pharmaceutical ingredient in prescription statin drugs. The lovastatin content in fruiting bodies is concentrated in the gills (lamellae). Preclinical studies in hypercholesterolemic rats demonstrate significant reductions in plasma total cholesterol (24%), triglycerides (46%), LDL cholesterol (63%), and LDL/HDL ratio (57%) with 5% dietary mushroom powder. In apolipoprotein E-deficient mice, 3% dietary P. eryngii for 10 weeks reduced total cholesterol and atherosclerotic lesion area.
• Lipid-lowering polysaccharides: P. eryngii polysaccharides from solid-state fermentation demonstrate lipid-lowering effects in both macrophage-derived foam cell models and zebrafish models, independent of the lovastatin content, suggesting complementary mechanisms.
• Anti-atherosclerotic properties: The combination of lovastatin, ergothioneine (antioxidant protection of endothelial cells), beta-glucans (cholesterol binding in the gut), and phenolic compounds provides a multi-target approach to cardiovascular risk reduction.

Secondary: Metabolic Support and Glycemic Control (Moderate Evidence)

• Postprandial glycemia: A randomized controlled crossover trial in metabolically unhealthy obese adults demonstrated that a meal containing P. eryngii improved postprandial glucose and insulin responses, enhanced fullness perception, reduced hunger, and suppressed ghrelin levels compared to a control meal.
• Body composition: A three-month RCT in metabolically unhealthy patients found that daily consumption of a P. eryngii snack, alongside conventional nutritional counseling, significantly reduced body weight, body fat, and waist and hip circumferences compared to counseling alone.
• Inflammation and oxidative stress: The same RCT demonstrated decreased IL-6 and oxidized LDL in the mushroom group — the first clinical demonstration that P. eryngii regulates inflammation and oxidative stress in humans.

Secondary: Antioxidant and Cellular Protection (Preliminary Evidence)

• Ergothioneine: P. eryngii is a significant dietary source of ergothioneine, a unique amino acid antioxidant transported into cells via the specific organic cation transporter OCTN1. Ergothioneine accumulates in tissues subject to high oxidative stress (liver, kidney, lens of the eye, bone marrow, erythrocytes) and protects against mitochondrial dysfunction, lipid peroxidation, and DNA damage. Emerging evidence supports roles in neurodegenerative, cardiovascular, and age-related disease prevention.
• Vitamin D2: When exposed to UV light, the ergosterol in P. eryngii is converted to vitamin D2, making UV-treated king oyster mushrooms one of the few non-animal dietary sources of vitamin D.

Emerging/Preclinical

• Immunomodulatory activity: Beta-glucan polysaccharides from P. eryngii stimulate macrophage activation and NK cell activity in vitro. Potential applications in immune support require clinical validation.
• Antitumor activity: Polysaccharide fractions demonstrate anti-proliferative effects against various cancer cell lines in vitro. No clinical evidence for anti-cancer efficacy in humans.
• Gut microbiome modulation: Beta-glucans are fermented by gut bacteria to produce short-chain fatty acids (SCFAs), which contribute to cholesterol reduction and intestinal health. Prebiotic effects have been demonstrated in animal models.
• Protein digestion effects: Recent research suggests P. eryngii beta-glucans may modulate protein digestion and the release of free amino acids into the bloodstream in obese adults.

Mechanism of Action

Primary Mechanisms

1. Lovastatin-mediated HMG-CoA reductase inhibition: Naturally occurring lovastatin in P. eryngii competitively inhibits 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in the mevalonate pathway of cholesterol biosynthesis. This is the same mechanism employed by prescription statin drugs. The lovastatin content is highest in the gills of the fruiting body. However, the amount of lovastatin in food-level mushroom consumption is substantially lower than in pharmaceutical statin doses, and the bioavailability of fungal lovastatin from whole mushroom matrices has not been fully characterized.

2. Polysaccharide-mediated lipid lowering: Beta-glucan polysaccharides from P. eryngii reduce lipid content through multiple complementary mechanisms: (a) binding bile acids in the gut, promoting fecal cholesterol excretion; (b) modulation of hepatic lipid metabolism; (c) fermentation by gut microbiota to produce propionate and other SCFAs that inhibit hepatic cholesterol synthesis. Metabolomic studies in high-fat diet-induced obese mice confirm modulation of lipid metabolic pathways.

3. Ergothioneine cytoprotection: Ergothioneine is absorbed into cells via the specific transporter OCTN1 (SLC22A4), where it functions as a potent intracellular antioxidant. It scavenges hydroxyl radicals, hypochlorous acid, and peroxynitrite; chelates redox-active metal ions; and protects mitochondrial function under oxidative stress. In endothelial cells, ergothioneine uptake via OCTN1 protects against oxidized LDL-mediated damage — directly relevant to its anti-atherogenic potential.

Secondary Mechanisms

• Postprandial glycemic regulation: The high dietary fiber content (particularly beta-glucans) slows gastric emptying and glucose absorption, moderating postprandial blood glucose and insulin spikes. The ghrelin-suppressive effect observed in clinical trials may be mediated by fiber-induced gut hormone modulation.
• Anti-inflammatory activity: Phenolic compounds (gallic acid, caffeic acid) and ergothioneine contribute to NF-kB pathway modulation and reduced production of pro-inflammatory cytokines (IL-6, TNF-alpha). Clinical reductions in IL-6 and oxidized LDL support this mechanism.
• Immunomodulation: Beta-glucans activate innate immune cells through dectin-1 receptor signaling, stimulating macrophage phagocytosis and NK cell cytotoxicity. This mechanism is shared across Pleurotus species and other medicinal mushrooms.
• Eryngiolide A: A unique sesquiterpene isolated from P. eryngii that demonstrates antibacterial activity against Bacillus subtilis and Bacillus cereus. Its contribution to the overall pharmacological profile of whole mushroom consumption is uncertain.

Clinical Evidence Summary

Clinical evidence for P. eryngii is emerging, with several well-designed human trials published in recent years, primarily focused on metabolic outcomes in overweight and obese populations.

Metabolic Outcomes

Lipid Lowering (Preclinical and Pleurotus Genus)

Pleurotus Genus Clinical Evidence

• Pleurotus ostreatus (Oyster Mushroom): A 2011 RCT (n=20) demonstrated that soup containing 30 g dried P. ostreatus daily for 21 days significantly decreased triglycerides, total cholesterol, and oxidized LDL. While this study used a different Pleurotus species, the shared bioactive profile (lovastatin, beta-glucans, ergothioneine) provides supportive evidence for the genus.

Evidence Limitations

• No large cardiovascular outcome trials: While metabolic surrogate markers (glucose, lipids, inflammatory markers) show improvement, no studies have evaluated hard cardiovascular endpoints (myocardial infarction, stroke, cardiovascular mortality).
• Small sample sizes: Existing human RCTs involve small numbers of participants, limiting generalizability.
• Lovastatin bioavailability gap: The amount of lovastatin in food-level consumption is orders of magnitude lower than pharmaceutical statin doses. The clinically relevant contribution of fungal lovastatin from whole mushroom consumption to cholesterol reduction has not been isolated from other bioactive mechanisms.
• Preclinical lipid data dominance: Most cholesterol-lowering evidence comes from animal models. Human lipid-lowering RCTs specific to P. eryngii (as opposed to the genus) are limited.
• Short study durations: Clinical trials span weeks to months; long-term cardiovascular effects of regular consumption are unknown.
• Whole food vs. extract: Clinical trials have used whole mushroom preparations. Effects of concentrated extracts may differ in magnitude and profile.

Safety Profile

General Assessment

Pleurotus eryngii has a long history of safe food consumption worldwide and is one of the most widely cultivated and consumed edible mushrooms. At food-level consumption, it is considered safe for the general population. Concentrated extracts and supplements have limited formal safety evaluation but are expected to share the favorable safety profile of the whole mushroom at reasonable doses.

Contraindications

• Mushroom allergy: Individuals with known allergy to Pleurotus species or other basidiomycete mushrooms should avoid consumption. Spore-related respiratory allergies have been documented in mushroom farm workers.
• Concurrent statin therapy: While food-level consumption is unlikely to produce clinically significant additive effects with pharmaceutical statins, concentrated lovastatin-rich extracts could theoretically amplify statin-related adverse effects (myopathy, rhabdomyolysis, hepatotoxicity). Patients on statin therapy should consult their physician before using concentrated P. eryngii supplements.

Drug Interactions

• Statin medications (atorvastatin, simvastatin, rosuvastatin): Theoretical additive HMG-CoA reductase inhibition from naturally occurring lovastatin. Clinical significance at food-level consumption is likely negligible, but concentrated extracts warrant caution.
• Anticoagulants: No specific interaction data. No known anticoagulant activity.
• Antidiabetic medications: Given the demonstrated glucose-lowering effects in clinical trials, additive hypoglycemic effects are theoretically possible with concentrated preparations. Monitor blood glucose if combining with insulin or oral hypoglycemics.

Side Effects (at Food-Level Consumption)

• Common: No significant adverse effects at normal dietary intake levels.
• Uncommon: Mild gastrointestinal discomfort (bloating, flatulence) from high fiber content, particularly in individuals not accustomed to mushroom consumption.
• Rare: Allergic reactions (skin rash, respiratory symptoms) in sensitized individuals. Occupational asthma from spore exposure in cultivation workers.

Toxicology

• General: No toxic effects reported from food consumption. P. eryngii is universally recognized as a safe edible mushroom.
• Heavy metals: As with all cultivated mushrooms, bioaccumulation of heavy metals from substrate materials is possible. Products from GMP-certified cultivation facilities with third-party testing are preferred.

Clinical Dosage

Whole Mushroom (Culinary Consumption)

• Dietary integration: 100—200 g fresh mushroom (equivalent to 10—20 g dried) per serving, several times per week
• Clinical trial dose: RCTs have used approximately 30 g dried mushroom powder equivalent incorporated into snacks or meals
• UV-exposed: Choose UV-treated mushrooms for enhanced vitamin D2 content (can contain >10 mcg vitamin D2 per 100 g when UV-exposed)

Dried Mushroom Powder

• Typical dose: 3—10 g/day of dried mushroom powder
• Preparation: Can be added to soups, smoothies, or taken in capsules
• Note: Lovastatin content varies significantly by cultivation conditions, harvest timing, and processing

Polysaccharide Extract

• Research doses: Polysaccharide fractions studied at various concentrations in preclinical models
• No standardized clinical dose has been established for concentrated polysaccharide extracts
• Extraction method: Hot-water extraction captures beta-glucans; ethanol extraction may capture lovastatin and ergothioneine

Ergothioneine Considerations

• Dietary source: P. eryngii is one of the richest dietary sources of ergothioneine among cultivated mushrooms
• Cooking stability: Ergothioneine is heat-stable and largely retained during cooking
• Bioavailability: Well absorbed via the specific transporter OCTN1 in the gastrointestinal tract

Form Selection Guidance

For cardiovascular and metabolic health support, regular dietary consumption of whole P. eryngii mushrooms provides the broadest spectrum of bioactives (lovastatin, beta-glucans, ergothioneine, fiber, vitamin D2) in a food matrix that supports bioavailability. Concentrated extracts may offer higher doses of specific compounds but lack the clinical validation of whole-mushroom consumption. The culinary versatility of king oyster mushrooms — grilling, roasting, stir-frying, and simmering — makes them one of the most practical medicinal mushrooms for regular dietary integration.

Sources

• Vlassopoulou M, Paschalidis N, Savvides AL, et al. Pleurotus eryngii improves postprandial glycaemia, hunger and fullness perception, and enhances ghrelin suppression in people with metabolically unhealthy obesity. Pharmacol Res. 2021;175:105979
• Leroux-Stewart J, Bhatt DL, et al. A randomized controlled trial on Pleurotus eryngii mushrooms with antioxidant compounds and vitamin D2 in managing metabolic disorders. Antioxidants. 2022;11(11):2113
• Alam N, Yoon KN, Lee TS, Lee UY. Dietary effect of Pleurotus eryngii on biochemical function and histology in hypercholesterolemic rats. Saudi J Biol Sci. 2011;18(4):403-409
• Mori K, Kobayashi C, Tomita T, Inatomi S, Ikeda M. Antiatherosclerotic effect of the edible mushrooms Pleurotus eryngii (Eringi), Grifola frondosa (Maitake), and Hypsizygus marmoreus (Bunashimeji) in apolipoprotein E-deficient mice. Nutr Res. 2008;28(5):335-342
• Yang Y, Zhao C, Diao M, et al. Lipid-lowering effect of the Pleurotus eryngii (King Oyster Mushroom) polysaccharide from solid-state fermentation on both macrophage-derived foam cells and zebrafish models. Polymers. 2019;11(3):483
• Hu Y, Li M, Wang S, Yue S, Shi L. Hypolipidemic mechanism of Pleurotus eryngii polysaccharides in high-fat diet-induced obese mice based on metabolomics. Front Nutr. 2023;10:1118923
• Kalaras MD, Richie JP, Calcagnotto A, Beelman RB. Mushrooms: a rich source of the antioxidants ergothioneine and glutathione. Food Chem. 2017;233:429-433
• Jayachandran M, Xiao J, Xu B. A critical review on health promoting benefits of edible mushrooms through gut microbiota. Int J Mol Sci. 2017;18(9):1934
• Roupas P, Keogh J, Noakes M, Margetts C, Taylor P. The role of edible mushrooms in health: evaluation of the evidence. J Funct Foods. 2012;4(4):687-709
• Reis FS, Barros L, Martins A, Ferreira ICFR. Chemical composition and nutritional value of the most widely appreciated cultivated mushrooms: an inter-species comparative study. Food Chem Toxicol. 2012;50(2):191-197
• Halliwell B, Cheah IK, Tang RMY. Ergothioneine — a diet-derived antioxidant with therapeutic potential. FEBS Lett. 2018;592(20):3357-3366
• Khatun K, Mahtab H, Khanam PA, Sayeed MA, Khan KA. Oyster mushroom reduced blood glucose and cholesterol in diabetic subjects. Mymensingh Med J. 2007;16(1):94-99

Connections

• Pleurotus genus: P. eryngii shares its lipid-lowering and immunomodulatory bioactive profile with Oyster Mushroom (P. ostreatus), which has more extensive clinical cholesterol-lowering data. Both species contain lovastatin, beta-glucans, and ergothioneine, though P. eryngii is distinguished by its thicker stem, higher ergothioneine content, and superior culinary properties.
• Cholesterol-lowering mushrooms: Compare with Shiitake (Lentinula edodes), which contains eritadenine — a distinct cholesterol-lowering compound that inhibits S-adenosylhomocysteine hydrolase rather than HMG-CoA reductase. The complementary mechanisms suggest potential synergy in dietary mushroom-based cardiovascular health strategies.
• Metabolic support fungi: The glycemic and metabolic benefits parallel those of Maitake (Grifola frondosa), which has demonstrated glucose-lowering effects via alpha-glucosidase inhibition and insulin sensitivity enhancement. Both mushrooms are premium culinary species, enabling therapeutic dietary integration.
• Ergothioneine sources: Among cultivated mushrooms, P. eryngii and P. ostreatus are among the richest sources of ergothioneine. Tremella (Tremella fuciformis) provides complementary antioxidant support through different mechanisms (polysaccharide-mediated).
• Functional food paradigm: King Oyster Mushroom exemplifies the “food as medicine” approach — its therapeutic potential is primarily realized through regular dietary consumption rather than concentrated supplementation, distinguishing it from fungi like reishi or chaga that are consumed primarily as medicines.